The highly anticipated Retatrutide 20mg device, a novel dual GIP and GLP-1 target , is currently under review by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. General availability https://buyretatrutideuk524301.newsyblog.com/246127/retatrutide-20mg-pen-uk-rollout-news